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encoding the CAT-3 cationic amino acid transporter, on 
chromosome X by exome sequencing in two brothers with 
autism spectrum disorder (ASD). We then sequenced the 
SLC7A3 coding sequence in 148 male patients with ASD 
and identified three additional rare missense variants in 
unrelated patients. Functional analyses of the mutant trans-
porters showed that two of the four identified variants cause 
severe or moderate loss of CAT-3 function due to altered 
protein stability or abnormal trafficking to the plasma 
membrane. The patient with the most deleterious SLC7A3 
variant had high-functioning autism and epilepsy, and also 
carries a de novo 16p11.2 duplication possibly contributing 
to his phenotype. This study shows that rare hypomorphic 
variants of SLC7A3 exist in male individuals and suggest 
that SLC7A3 variants possibly contribute to the etiology 
Abstract Cationic amino acid transporters (CATs) medi-
ate the entry of L-type cationic amino acids (arginine, orni-
thine and lysine) into the cells including neurons. CAT-3, 
encoded by the SLC7A3 gene on chromosome X, is one of 
the three CATs present in the human genome, with selec-
tive expression in brain. SLC7A3 is highly intolerant to 
variation in humans, as attested by the low frequency of 
deleterious variants in available databases, but the impact 
on variants in this gene in humans remains undefined. In 
this study, we identified a missense variant in SLC7A3, 
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of ASD in male subjects in association with other genetic 
factors.
Keywords Cationic amino acid transporter · Autism 
spectrum disorders · Exome sequencing · Chromosome X · 
Oligogenism
Abbreviations
ASD  Autism spectrum disorders
CAT  Cationic amino acid transporter
CNV  Copy number variants
LOH  Loss of heterozygosity
MAF  Minor allele frequency
mTOR  Mammalian target of rapamycin
NO  Nitric oxide
Introduction
The main function of cationic amino acid transporters 
(CAT) is to mediate the entry of l-type cationic amino 
acids (i.e., l-arginine, l-ornithine and l-lysine) into many 
different cell types including neurons (Closs et al. 2006; 
Jager et al. 2013). Their function is crucial since lysine 
and arginine, under certain conditions, are essential amino 
acids that are derived exclusively from the degradation of 
ingested nutrients. The CAT family comprises three differ-
ent genes: SLC7A1/CAT-1 on chromosome 13, SLC7A2/
CAT-2 on chromosome 8, and SLC7A3/CAT-3 on chro-
mosome X. All three transporters have different and com-
plementary tissue localizations, making each of them 
necessary for life and normal health. CAT-3 is selectively 
expressed in brain in rodents (Hosokawa et al. 1997; 
Ito and Groudine 1997). In neurons, CAT-3 responds to 
NMDA receptor activation and regulates the mammalian 
target of rapamycin (mTOR) signaling pathway, which 
has a central role in neuronal development and plasticity, 
through arginine availability (Huang et al. 2007).
Autism spectrum disorders (ASD) are neurodevelop-
mental disorders characterized by impaired social interac-
tions and communication, restricted interests and repetitive 
or stereotyped behaviors (Lai et al. 2014). Intellectual dis-
ability (ID) is a frequent comorbidity of ASD, present in 
more than half of ASD subjects (Srivastava and Schwartz 
2014; Tuchman and Rapin 2002; Amiet et al. 2008). ASD 
are highly genetically determined, but the genetic fac-
tors involved in these disorders are extremely heterogene-
ous and have proven difficult to identify (Betancur 2011; 
Huguet et al. 2013; Jeste and Geschwind 2014), and, 
in spite of the acceleration of gene identification due to 
technological advances, a genetic cause is still found in a 
minority of ASD cases. De novo or inherited copy num-
ber variants (CNV), strongly associated with autism and 
probably conferring high susceptibility to ASD, have been 
identified in 2–10 % of patients (Girirajan et al. 2013; 
Sanders et al. 2011; Glessner et al. 2009; Bucan et al. 2009; 
Pinto et al. 2010; Huguet et al. 2013). Additional copies of 
the 15q11–q13 region or an abnormal number of copies in 
the 16p11.2 region are examples of recurrent CNVs found 
in ASD (Sanders et al. 2011; Depienne et al. 2009; Weiss 
et al. 2008; Kumar et al. 2008; Nava et al. 2014b; Levy 
et al. 2011). More recently, exome sequencing of parent–
offspring trios has shown that de novo point mutations con-
tribute to ASD in 10–30 % of sporadic patients (Murdoch 
and State 2013; Krumm et al. 2014; O’Roak et al. 2011, 
2012; Sanders et al. 2012; Neale et al. 2012; Iossifov et al. 
2012, 2014). These studies predicted that ASD could result 
from genetic abnormalities in several hundreds of different 
genes, many of which are, nonetheless, interconnected or 
part of common functional pathways (Neale et al. 2012; 
O’Roak et al. 2012; Sanders et al. 2012; Iossifov et al. 
2012; Gilman et al. 2011). Examples of pathways repeat-
edly involved in ASD include: synaptic function, illustrated 
by mutations in SHANK1-3 scaffolding proteins, neuroli-
gins, neurexins, contactins and contactin-associated pro-
teins encoding genes; the mTOR pathway, illustrated by 
mutations in TSC1/TSC2 or PTEN that cause syndromic 
forms of ASD; chromatin remodeling; and Wnt signaling 
(Krumm et al. 2014; Jeste and Geschwind 2014; Huguet 
et al. 2013). An excess of males (4 affected males for one 
affected female) is typically observed in ASD (Schaafsma 
and Pfaff 2014; Werling and Geschwind 2013), suggest-
ing that genes located on sex chromosomes contribute 
to the etiology of the disorders, or that the penetrance of 
autistic traits depends on sex determinants (Werling and 
Geschwind 2013).
In this study, we used exome sequencing to identify 
genetic factors contributing to ASD in a family compris-
ing two affected brothers. The identification of a missense 
variant in SLC7A3 on chromosome X, shared by the two 
brothers, prompted us to investigate the consequences and 




Exome sequencing was performed in Family 505, originat-
ing from Morocco, and comprising two affected brothers 
born of consanguineous parents (Fig. 1a). The proband (01) 
had a normal motor development but presented with lan-
guage delay. He was diagnosed with autistic spectrum dis-
order associated with moderate intellectual disability. He 
had obsessive–compulsive behaviors, phobias and sleeping 
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difficulties. His affected brother (02) had a clinical history 
similar to that of his older brother but he had more severe 
intellectual disability and never acquired language (Supple-
mentary material). A younger half-brother had a language 
delay at the age of 3 years, and 2 maternal cousins had ID 
with unspecified behavioral disturbances. DNA was una-
vailable from the father and the cousins.
Sequencing of SLC7A3 was then performed in 148 male 
subjects with ASDs recruited in the “Centre de Référence 
Déficiences Intellectuelles de Causes Rares” and the “Cen-
tre Diagnostic Autisme” (Pitié-Salpêtrière Hospital, Paris, 
France) (Nava et al. 2014b). Index cases were assessed 
with the Autism Diagnostic Interview-Revised (ADI-R) 
and had ASD based on DSM IV-TR criteria: 120 index 
cases (81 %) had autism with ID and 28 (19 %) had Asper-
ger syndrome or high-functioning autism; 82 % (122/148) 
of ASD patients were sporadic cases.
The study was approved by the local Institutional 
Review Board (Comité de Protection des Personnes, Hôpi-
tal Pitié-Salpêtrière, Paris, France). Informed written con-
sent was obtained from each subject or his parents or legal 
representatives before blood sampling. Genomic DNA of 
patients and relatives was extracted from blood cells using 
standard phenol–chloroform procedures. Cerebrospinal 
fluid (CSF) sampling in subject 02 of family 505 was per-
formed in a diagnostic context.
SNP array analysis
The affected brothers and their healthy sister were geno-
typed using cytoSNP-12 microarrays (Illumina, San Diego, 
CA). Automated Illumina microarray experiments were 
performed as previously described (Nava et al. 2014b). 
Image acquisition was performed using an iScan System 
Fig. 1  Identification of missense variants in SLC7A3 in four patients 
with ASD. a Pedigree of the families and segregation of SLC7A3 
variants; m and m/+ denotes male or female individuals carrying one 
variant in the hemizygous or heterozygous state, respectively. Arrow 
the index case. Black symbols individuals diagnosed with ASD; gray 
symbols patients with undetermined intellectual disability or learning 
difficulty phenotypes (see details in Supplementary data). b Sequence 
electropherograms showing the SLC7A3 variants in the hemizygous 
state in the affected individuals of Families 505 (01, 02), 885, 388, 
962 (P), in the heterozygous state in the mother of Family 505 (05) 
and their absence in an unaffected brother in Family 505 (03) and 
controls (C). c Alignment of the regions flanking the SLC7A3/CAT-3 
missense variant in orthologous proteins showing the conservation 
of the altered amino acids. d Schematic model of the CAT-3 protein 
showing the putative location of the amino acid residues altered by 
the variants
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(Illumina). Image analysis and automated CNV calling was 
performed using GenomeStudio v2011.1 and CNVPartition 
v3.1.6 with the default confidence threshold of 35. Loss 
of heterozygosity (LOH) regions with a size >2 Mb were 
determined using CNVPartition v3.1.6.
Exome sequencing
The exome of the two affected brothers in family 505 and 
their unaffected mother was sequenced by Integragen SA 
(Evry), as previously described (Nava et al. 2014a). Rare 
coding variants or variants predicted to alter consen-
sus splice sites with a read depth ≥10 shared by the two 
affected brothers were listed using the ERIS interface (Inte-
gragen). Rare variants were defined by a minor allele fre-
quency (MAF) ≤1 % in Hapmap, 1000 Genomes, Exome 
variant server, and in an in-house Integragen exome data-
base. Further analysis of exome data focused on the search 
for homozygous mutations located in identical-by-descent 
regions or hemizygous variants on chromosome X. Possi-
bly deleterious variants were defined as indels introducing 
frameshifts or in-frame insertions or deletions, nonsense 
or splice-site mutations, mutations altering start or termi-
nation codons, or nonsynonymous variants predicted to be 
possibly deleterious by at least one of three prediction algo-
rithms (see bioinformatics analyses).
Sanger sequencing
Specific primer pairs were designed to confirm the vari-
ants detected by exome sequencing in SLC7A3, CCDC120, 
ARAF, FAM123B and SLC9A6 on chromosome X, and 
SCN2A, MAS1L, FOXP2, ROBO4, NOS1, PARP4, CAC-
NAIH, ZSCAN10, TRAP1 and TMPRSS9 on autosomal 
chromosomes and to study their segregation in rela-
tives. The exons and intron–exon junctions of SLC7A3 
(NM_001048164.2) were amplified and analyzed using 
11 primer pairs (Table S1). Forward and reverse sequence 
reactions were performed with the Big Dye Termina-
tor Cycle Sequencing Ready Reaction Kit (Applied Bio-
systems, Foster City, California). G50-purified sequence 
products were run on an ABI 3730 automated sequencer 
(Applied Biosystems); the data were analyzed with Seqs-
cape v2.6 software (Applied Biosystems).
Bioinformatic and statistical analyses
Missense variants were assessed in silico for possible 
pathogenicity using Alamut 2.3 (Biointeractive Software, 
France), PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2), SIFT (http://sift.bii.a-star.edu.sg), and Mutation 
Taster (www.mutationtaster.org). A three-dimensional 
model of the first predicted 10 TMDs of hCAT-3 was 
generated as previously described for hCAT-2A (Beyer 
et al. 2013). Comparison of the number of SLC7A3 variants 
in male ASD patients versus males of the ESP population 
(n = 2443, Exome variant server, http://evs.gs.washington.
edu/EVS/) or male control subjects included in the IPDGC 
study (n = 338) was performed with the Fisher’s Exact 
Test. The probability to identify at least n variants in 
SLC7A3 in the tested patient population was calculated 
based on the frequency of SLC7A3 rare variants in the ESP 
and IPDGC populations using a binomial distribution.
Immunofluorescence staining and isolation of plasma 
membrane proteins
Missense variants identified in autistic patients were intro-
duced into plasmids expressing the human CAT-3 cDNA 
fused to the Green Fluorescent protein (GFP). Cos7 cells 
were transiently co-transfected with 5 µg of WT or mutant 
CAT-3 expression plasmids using a neon electroporation 
system (Invitrogen). Cells were fixed with 4 % paraform-
aldehyde (PFA) 24 h after transfection, permeabilized with 
0.1 % Triton X-100, and incubated with anti-calreticulin 
(ER marker, Abcam, ab2907, 1:1000) for at least 2 h at 
room temperature. The signal was revealed by incuba-
tion with a Cy3-coupled sheep anti-mouse IgG antibody 
(Sigma, 1:1000) for 1 h at room temperature. Nuclei were 
stained with Hoechst (1:1000). Fluorescent images were 
acquired with a confocal system (Leica SP2 AOBS AOTF).
Proteins present at the plasma membrane of Cos7 trans-
fected cells were isolated following surface biotinylation of 
living Cos7 cells with the Cell Surface Protein Isolation Kit 
(Pierce), following the manufacturer’s recommendations. 
Proteins were resolved by SDS-PAGE on 4–12 % gradient 
gels (Invitrogen) and electrotransferred onto nitrocellulose 
membranes. CAT-3 was probed with an anti-GFP antibody 
(monoclonal mouse anti-GFP antibody, #11814460001, 
Roche, 1:4000), and the signal was revealed by enhanced 
chemiluminescence (Pierce). The membranes were sub-
sequently probed with an anti-Tom20 (BD Biosciences 
612278, 1:1000) antibody to confirm plasma membrane 
enrichment, and with an anti-Flotillin-1 (BD Biosciences 
610820, 1:1000) antibody for normalization. The ImageJ 
program (http://rsb.info.nih.gov/ij/) was used for signal 
quantification. Independent measures from at least 3 dif-
ferent experiments were analyzed with the Mann–Whitney 
test.
Transporter expression and transport studies 
in Xenopus laevis oocytes
cRNA was prepared by in vitro transcription from the SP6 
promoter of CAT-3-GFP-pSP64T (mMessage mMachine 
in vitro transcription kit, Ambion Inc, Austin, TX, USA) 
2651Hypomorphic variants of cationic amino acid transporter 3 in males with autism spectrum…
1 3
(Vekony et al. 2001). Seventeen nanograms of human 
CAT-3-GFP cRNA were injected into each X. laevis oocyte 
(Dumont stages V–VI). Noninjected oocytes were used 
as controls. Arginine uptake was determined 3 days after 
injection of cRNA as previously described (Closs et al. 
1997). Briefly, oocytes were washed in uptake solution 
(100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 
5 mM HEPES, 5 mM Tris, pH 7.5) containing 1 mM unla-
beled arginine then transferred to the same solution sup-
plemented with 0.37 MBq/ml L-[2,3,4-3H]arginine mono-
hydrochloride (MP), 1.59TBq/mmol. After incubation for 
15 min at 20 °C, the oocytes were washed four times in 
ice-cold uptake solution and solubilized individually in 2 % 
sodium dodecyl sulfate (SDS). The incorporated radioac-
tivity was quantified in a liquid scintillation counter (Tri-
Carb 2810 TR, Perkin Elmer).
Oocyte lysates and biotinylation of cell surface proteins
All steps were performed at 4 °C, as previously described 
(Beyer et al. 2013). Briefly, ten oocytes were each incubated 
for 30 min with membrane impermeable EZ-Link™Sulfo-
NHS-SS-Biotin (Sulfosuccinimidyl-2-(biotinoamido)ethyl-
1,3-dithiopropionate, Thermo Fisher Scientific Inc., Rock-
ford; 1 mg/ml in PBSmod/CM). The biotinylation reaction 
was stopped by incubating the oocytes in PBSmod contain-
ing 50 mM NH4Cl for 10 min. After lysis in 200 μl radio-
immune precipitation assay buffer (RIPA: 1 % deoxycho-
late, 1 % Triton X-100, 0.1 % SDS, 150 mM NaCl, 2 mM 
MgCl2, 10 mM Tris–HCl pH 7.2) containing protease inhib-
itors (Complete Mini EDTA-free protease inhibitor tablets, 
Roche, Basel), an aliquot of each whole oocyte lysate was 
mixed directly with an equal volume of 2 × sample buffer 
(125 mM Tris base, 20 % glycerol (v/v), 5 % SDS, 0.001 % 
bromphenol blue (m/v), 8 M urea, 2 % mercaptoethanol) 
and incubated for 10 min at 37 °C. The remaining lysate 
was incubated overnight with avidin-coated Sepharose 
beads (NeutrAvidin® UltraLink® Resin, Thermo Fisher 
Scientific Inc., Rockford) to recover the biotinylated sur-
face proteins. The beads were then washed three times 
with RIPA containing protease inhibitors (PMSF 200 µM). 
Biotinylated proteins were released from the beads by incu-
bation in 2× sample buffer for 10 min at 37 °C. Oocytes 
lysates were then separated by 7.5 or 12.5 % SDS-PAGE 
and tank-blotted onto nitrocellulose membranes, as pre-
viously described (Beyer et al. 2013). CAT-3 proteins on 
the blots were stained by incubation with rabbit polyclonal 
GFP antibody (Clontech Living colors #632460, 1:3000) 
overnight at 4 °C followed by goat anti-rabbit IgG, H&L 
chain-specific peroxidase conjugate (Calbiochem #401393, 
1:15,000) for 1 h at room temperature. The blots were then 
incubated for 1 min with the chemiluminescence reagent 
(Western Lightning® ECL-Plus, Perkin Elmer, USA) and 
exposed to chemiluminescence films (Hyperfilm ECL, GE 
Healthcare Life Sciences, UK). Signal intensity was quan-
tified using Chemidoc® XRS with Quantity One software 
(BioRad, Berkeley, USA). For standardization, membranes 
were stained with a mouse monoclonal anti-ß-tubulin anti-
body (T 4026, Sigma-Aldrich, Deisenhofen, 1:5000) and 
a rabbit anti-mouse IgG peroxidase conjugate (A 9044, 
Sigma-Aldrich, Deisenhofen, 1:5000).
Results
Family 505 comprises two brothers with ASD born from 
North African consanguineous parents. To identify vari-
ants contributing to ASD, we sequenced the exome of the 
brothers and their healthy mother (Fig. 1a). The affected 
brothers and their healthy sister were genotyped, in paral-
lel, using Illumina SNP arrays. No pathogenic CNV were 
detected by this analysis in the affected sibs. Two LOH 
regions shared by the affected brothers and absent from 
their sister, a 2.3 Mb region on chromosome 8 and a 7 Mb 
region on chromosome 15, containing 28 and 39 genes, 
were found (Fig. S1 and Table S2). Exome sequencing 
detected 351 rare variants shared by the affected brothers 
that altered the coding sequence or consensus splice sites in 
329 genes (Table S3). None of the variants was located in 
LOH regions.
Since two maternal male cousins were reported to have 
unspecified ID and behavioral disturbances, we decided to 
focus our study on X-chromosomal variants. Three non-
synonymous variants predicted to be possibly deleterious 
by at least one prediction tool were located on chromo-
some X (c.624G > C/p.Gln208His in ARAF, c.991G > A/p.
Ala331Thr in SLC7A3, c.1477G > A/p.Ala493Thr in 
CCDC120). Analyses of North African control subjects 
showed that the frequency of the variants in ARAF and 
CCDC120 was higher than reported in databases in other 
populations, making their involvement in the phenotype of 
the brothers unlikely; the c.991G > A/p.Ala331Thr variant 
in SLC7A3 was not found, however, in 630 controls includ-
ing 440 North African subjects (Table S4).
We then screened 148 unrelated males with ASD for 
mutations in exons of SLC7A3. We identified three rare 
hemizygous variants that altered conserved amino acids in 
three patients (Fig. 1): c.1289A > G/p.Tyr430Cys was iden-
tified in a 10-year-old boy with high-functioning autism 
and epilepsy, whereas c.1766G > C/p.Ser589Thr and 
c.1784G > C/p.Ser595Thr were identified in patients with 
ASD and ID.
To investigate the functional consequences of the iden-
tified SLC7A3 missense variants, we analyzed the cellu-
lar distribution and transport activities of the four mutant 
CAT-3 transporters. We first compared the subcellular 
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localization of transiently expressed WT and mutant CAT-3 
proteins fused to GFP in mammalian Cos7 cells. Distribu-
tion of p.Tyr430Cys-CAT-3 appeared to be restricted to 
the endoplasmic reticulum (ER), whereas WT and other 
types of mutant CAT-3 were mostly present at the plasma 
membrane (Fig. 2a). By labeling plasma membrane pro-
teins with biotin on the extracellular face of intact cells, we 
confirmed that the amount of p.Tyr430Cys-CAT-3 at the 
plasma membrane, as well as the overall amount of protein, 
decreased strongly in comparison to WT CAT-3 (Fig. 2b, 
c). These results suggest that p.Tyr430Cys-CAT-3 is unsta-
ble or trapped in the ER where it is degraded.
Further studies in Xenopus laevis oocytes showed 
that transport activities were reduced in oocytes express-
ing p.Tyr430Cys and p.Ser589Thr compared to oocytes 
expressing WT CAT-3 (Fig. 3a). Overall, expression of 
p.Tyr430Cys and p.Ser589Thr proteins was also reduced. 
The reduction was more pronounced in the plasma mem-
brane fraction, especially for p.Tyr430Cys (Fig. 3b, c). 
Altogether, these findings confirmed that two of the four 
SLC7A3 variants identified had deleterious effects on 
CAT-3 protein function.
The p.Ala331Thr variant did not alter the cellular dis-
tribution of the overexpressed transporter or its transport 
activity in Xenopus laevis oocytes; we then hypothesized 
that it may have an effect on CAT-3 that was not detected 
by the tests we performed. We then assayed arginine, orni-
thine, and lysine in the CSF of one of the affected brothers 
with p.Ala331Thr (individual 505-02) sampled in a diag-
nostic context. Ornithine was slightly decreased in his CSF 
(5 µmol/L; normal range 7–11 µmol/L), suggesting that a 
misbalance of cationic amino acids possibly results from 
CAT-3 dysfunction.
CAT-3 has been reported to be specifically expressed in 
the brain during embryonic development, suggesting that 
SLC7A3 plays a role for in brain development, but this find-
ing is controversial (Hosokawa et al. 1997, 1999; Ito and 
Groudine 1997; Closs 2002; Vekony et al. 2001; Jager et al. 
2013). We therefore developed a quantitative RT-PCR assay 
to monitor the expression of CAT-3 in the developing mouse 
brain. SLC7A3 expression increased from embryonic day 12 
(E12) to post-natal day 7 (P7) and declined thereafter; gene 
expression was strongest in the diencephalon (Fig. S2). In 
contrast, SLC7A3 was expressed at very low levels in other 
tissues including heart and liver. These results are consistent 
with the expression pattern of SLC7A3 in the Human Brain 
Transcriptome Database, which also showed that expression 
of CAT-3 was higher in the developing human brain.
Fig. 2  Subcellular localization and expression of CAT-3 mutants at 
the plasma membrane in mammalian cells. a Subcellular localization 
of wild-type and mutant (p.Tyr430Cys, p.Ala331Thr, p.Ser589Thr, 
p.Ser595Thr) CAT-3 proteins and colocalization with endoplasmic 
reticulum (ER, marked using anti-calreticulin) observed by confocal 
microscopy. Scale bar 20 µm. b Representative western blot of WT 
and mutant CAT-3 protein expression in whole lysates and plasma 
membranes. Flotillin and Tom20 stainings were used to control mem-
brane protein enrichment and normalize protein load, respectively. c 
Quantification of WT and mutant CAT-3 proteins present in whole 
lysates and plasma membranes. The values, obtained from at least 
three different experiments, were compared with the Mann–Whitney 
test; *p < 0.05
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Discussion
In this study, we identified missense variants in SLC7A3, a 
gene encoding a CAT specifically expressed in the develop-
ing brain, in four male subjects with ASD. We showed evi-
dence that two of the identified variants lead to a severe or 
moderate loss of function of the CAT-3 transporter. This is 
the first study showing that hypomorphic SLC7A3 variants 
exist in the human male population.
SLC7A3 is highly intolerant to variation in humans, as 
shown by the absence of variants introducing premature ter-
mination codons in ~61.000 subjects of the ExAc database 
(http://exac.broadinstitute.org/gene/ENSG00000165349) 
and the absence of deletion encompassing SLC7A3 in 
the DGV database. The absence of variants invalidat-
ing SLC7A3 in thousands of control individuals strongly 
supports the assumption that complete loss of function 
of CAT-3 is lethal or pathogenic in humans. Constitutive 
CAT-3 deficiency was previously hypothesized to be lethal 
at an early embryonic stage in mammals (Closs et al. 2006). 
Indeed, CAT-1-deficient mice die rapidly after birth (Per-
kins et al. 1997), and the spared prenatal development of 
CAT-1-deficient mice is thought to result from the high lev-
els of CAT-3 expressed in embryonic tissues (Ito and Grou-
dine 1997; Nicholson et al. 1998). In contrast, several dele-
tions encompassing SLC7A3 among other genes have been 
reported in affected females in Decipher. A single male 
patient with a deletion of ~93 Mb encompassing SLC7A3 
(Decipher ID: 284367) is present in Decipher; interestingly, 
this patient has a syndromic form of autism and develop-
mental delay with additional dysmorphic and neurologic 
features. In this study, three missense variants were identi-
fied out of 148 males with ASD. This proportion (2 %) is 
higher to the frequency of SLC7A3 variants observed in the 
ESP male population (8 ‰, 20/2443) or in male individuals 
of the IPDGC study (3 ‰, 1/338) (Table S5), although the 
differences are not significant (p = 0.11) due to the small 
number of variant carriers in each population. However, 
the probability to observe 3 or more variants among 148 
individuals by chance based on the frequency of SLC7A3 
variants in control populations is very low (p = 0.05), 
supporting an excess of SLC7A3 variants in patients with 
ASD. The contribution of variants on chromosome X has 
been well demonstrated in ID but remains unclear in ASD 
in spite of an excess of affected males in both disorders. 
Indeed, the most recent studies on ASD genetic factors 
using whole exome or genome sequencing have focused on 
de novo mutations and have neglected the role of variants 
on chromosome X (Murdoch and State 2013; Krumm et al. 
2014; O’Roak et al. 2011, 2012; Sanders et al. 2012; Neale 
et al. 2012; Iossifov et al. 2012, 2014).
Cationic amino acid supplies in cells, and therefore 
CAT-mediated transport, are critical for arginine-, lysine- 
and ornithine-dependent metabolic reactions. In particu-
lar, arginine is the precursor for the synthesis of nitric 
oxide (NO), creatine and urea, and ornithine is the start-
ing point for polyamine synthesis. In this context, at least 
two different consequences of SLC7A3 dysfunction can be 
hypothesized. On the one hand, since NO is an important 
cell–cell signaling molecule in the central nervous system 
(Braissant et al. 1999), reduced availability of arginine in 
the brain could alter NO synthesis and signaling. In favor 
of this hypothesis, mice deficient in Nos1, which encodes 
Fig. 3  Analysis of WT and 
mutant CAT-3 transport activity, 
expression and localization 
in Xenopus laevis oocytes. 
a Transport of 100 µM [3H]
L-arginine for 15 min into 
oocytes. b Representative 
Western Blot of WT and mutant 
CAT-3-EGFP proteins in whole 
cell lysates and at the plasma 
membrane. c Quantification of 
three independent experiments 
as shown in b, left columns 
CAT-3 in total cell lysate, right 
columns in plasma membrane 
protein fraction
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the neuronal NO synthase (nNOS) that converts arginine to 
NO, display cognitive impairments, aggressivity and hyper-
activity as well as additional behavioral abnormalities (Nel-
son et al. 1995; Weitzdoerfer et al. 2004; Tanda et al. 2009). 
On the other hand, arginine availability also regulates the 
mammalian target of rapamycin (mTOR) pathway that con-
trols the survival, differentiation and development of neu-
rons and synaptic plasticity, among other functions (Swiech 
et al. 2008); reduced CAT-3 activity would therefore be 
expected to have an impact on the mTOR pathway, which 
has previously been shown to be impaired in several forms 
of ASD (Bourgeron 2009; Ehninger and Silva 2011; Veen-
stra-VanderWeele and Blakely 2012). In particular, CAT-3 
variants could modulate the effects of NMDA receptor acti-
vation on the mTOR pathway (Fig. 4) (Huang et al. 2007).
Although our results suggest that loss of function of 
CAT-3 is the main consequence of the identified missense 
variants, the functional tests performed did not permit to 
confirm this hypothesis for the p.Ala331Thr, initially iden-
tified in Family 505. In spite of the absence of functional 
effect of this variant on cellular localization and trans-
porter activity, genetic data (absence of this variant from a 
matched control population, segregation with the disease in 
the family) support a possible deleterious effect of this vari-
ant. In addition, one of the affected brothers had low values 
of ornithine in his CSF possibly related to a CAT-3 dys-
function. Our hypothesis is therefore that this variant alters 
an untested function of the CAT-3 transporter. p.Ala331Thr 
is located in an epitope exposed at the extracellular sur-
face (Fig. 1); it could then alter the interaction of CAT-3 
with a putative ligand. Mouse CAT-1 has been shown to be 
a receptor for retroviruses (Kim et al. 1991). CAT-3 could 
be a receptor for a cellular signal during development, 
although this remains to be demonstrated.
The patient with the most deleterious effect on CAT-3 
activity (patient 885, p.Tyr430Cys) had typical autism dur-
ing childhood but his evolution was favorable and he was 
diagnosed at 10 years old with high-functioning autism. 
The preferential expression of CAT-3 during embryogen-
esis suggests that CAT-3 dysfunction has a negative effect 
during early brain development. This deficit could therefore 
partially improve or recover with time due to compensa-
tory expression of other CATs, such as CAT-1, as observed 
for this patient. This patient also had a de novo duplication 
on chromosome 16p11.2, previously identified by SNP 
array (Nava et al. 2014b), that possibly contributes to his 
phenotype. Recurrent reciprocal deletions and duplica-
tions involving the 600 Kb 16p11.2 region were repeatedly 
associated with ASD and schizophrenia, but are character-
ized by a great phenotypic variability and low penetrance 
and do not segregate perfectly with ASD in multiplex 
families (Sanders et al. 2011; Depienne et al. 2009; Weiss 
et al. 2008; Kumar et al. 2008; Nava et al. 2014b; Levy 
et al. 2011). The 16p11.2 duplication by itself could then 
not be considered as the sole cause of ASD in this patient. 
We hypothesize that the disorder could then result from the 
association of p.Tyr430Cys in SLC7A3 and the 16p11.2 
duplication, and eventually other variants in the genome. 
The possibility of oligogenism, suspected in many cases of 
ASD, has been supported by several recent studies (Schaaf 
et al. 2011; Barrett et al. 1999; Chilian et al. 2013; Heil and 
Schaaf 2013; Jiang et al. 2004; Junaid and Pullarkat 2001; 
Fig. 4  Schematic diagram 
showing the possible conse-
quences of SLC7A3 dysfunc-
tion on the mTOR and NO 
pathways. Reduced availability 
of intracellular cationic amino 
acids, including arginine, could 
decrease NO synthesis and alter 
NO-mediated signaling (on the 
left) or negatively affect the 
mTOR signaling pathway in 
neurons (on the right)
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Leblond et al. 2012), but identification of the factors inter-
acting together to cause the disorder constitutes a real chal-
lenge. Observations on mice suggest that genes functioning 
in same pathways are more susceptible to display dosage-
sensitive genetic interactions (Kidd et al. 1999; Hafezpar-
ast et al. 2002). Another possibility is that a burden of rare 
variants in unconnected genes predisposes to autism in an 
individual (Veltman and Brunner 2010).
Among the variants shared by the affected sibs in Family 
505 was a missense variant (NM_ 000620: p.Arg1369Cys) 
in NOS1. The two variants in SLC7A3 and NOS1 could 
have additive effects, decreasing both the availability of 
arginine and the conversion of arginine to NO in neurons. 
Among the variants present in the two brothers possibly 
contributing to autism was a missense variant in SCN2A, 
also present in their unaffected sister, as well as a missense 
variant in CACNA1H gene, encoding a calcium channel, 
and missense variant in FOXP2, encoding a forkhead-
box DNA-binding domain containing transcription factor 
required for proper development of speech and language, 
which are both inherited from the healthy mother (Table 
S3). Variants in CACNA1H have previously been identi-
fied in patients with ASD, however, they did not segregate 
with ASD phenotypes, suggesting that they are not causa-
tive alone, although they could contribute to the phenotype 
(Splawski et al. 2006). Mutations in FOXP2 cause devel-
opmental language disorders in humans (Lai et al. 2001). 
Their contribution to ASD has been extensively been stud-
ied (Gauthier et al. 2003; Newbury et al. 2002; Wassink 
et al. 2002). However, the presence of the missense variant 
in the healthy mother suggests that this variant is not suf-
ficient to explain the phenotype of the brothers on its own 
but it could be part of the cause of their language impair-
ment. Further studies are therefore needed to confirm the 
contribution of SLC7A3 variants to ASD and apprehend the 
genetic interactions in individual cases.
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